Should 123I-MIBG scintigraphy be part of the workup for pheochromocytomas?

Nature Clinical Practice Endocrinology and Metabolism

Volumn 5, Issue 2, 2009, Pages 76-77

  Koch, Christian A ^a,b,c  

^a Department of Medicine ^*

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; METADRENALIN;

ADRENAL TUMOR; CANCER DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; HUMAN; INTERMETHOD COMPARISON; ISOTOPE LABELING; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCINTIGRAPHY; TUMOR VOLUME;

EID: 58849113931     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet1047     Document Type: Note

References (7)

1. Lenders JW et al. (2005) Phaeochromocytoma. Lancet 366: 665-675
2. Erickson D et al. (2001) Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab 86: 5210-5216
3. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf) 69: 181-188
4. 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med 49: 1232-1237
5. 123 metaiodobenzylguanidine scintigraphy routinely necessary before initial adrenalectomy for pheochromocytoma? Surgery 134: 918-922
6. Greenblatt DY et al. (2008) The utility of metaiodobenzylguanidine (MIBG) scintigraphy in patients with pheochromocytoma. Ann Surg Oncol 15: 900-905
7. Mackenzie IS et al. (2007) The use of 18- fluorodihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma. Eur J Endocrinol 157: 533-537